SCHEMBL17737439

SCHEMBL17737439

O=S(=O)(Nc1ccc(-c2ccccc2)cc1)c1cccc2cnccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.54
▸ PRKD3 O94806 2/20 0.54
▸ PRKCG P05129 2/20 0.54
▸ PRKCB P05771 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2D6 P10635 2/20 0.54
▸ PRKCA P17252 2/20 0.54
▸ NFKB1 P19838 2/20 0.54
▸ PRKCH P24723 2/20 0.54
▸ PRKCI P41743 2/20 0.54
▸ PRKCE Q02156 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ PRKCQ Q04759 2/20 0.54
▸ PRKCZ Q05513 2/20 0.54
▸ PRKCD Q05655 2/20 0.54
▸ PRKD1 Q15139 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ PRKACA P17612 1/20 0.54
▸ PRKACG P22612 1/20 0.54
▸ PRKACB P22694 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737761 0.92 PRKD3 (0.59) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL17737346 0.85 MEN1 (0.60) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL21999614 0.81 ACLY (0.61) KCNA5
SCHEMBL527108 0.79 CYP17A1 (0.53) TP53TSHRPGRCYP17A1PTPN2
SCHEMBL17737682 0.78 MEN1 (0.56) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL9484358 0.77 CYP17A1 (0.68) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL9484815 0.77 PRKD3 (0.46) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL17737766 0.76 IDO1 (0.61) MEN1KMT2ALMNAMAPK1
SCHEMBL10978592 0.76 PRKCG (0.70) MEN1PRKD3PRKCGPRKCBCYP3A4
SCHEMBL7481978 0.76 PRKCG (0.68) MEN1PRKD3PRKCGPRKCBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 — — US disclosed
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD. (GB) 2018-02-08 — — US disclosed
WO-2016071283-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 MEN1 3424/4885PRKD3 2755/4885PRKCG 4713/4885
US-20180037553-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE TDO2, IDO2, IDO1 MEN1 3424/4885PRKD3 2755/4885PRKCG 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback